UK-based start-up Skin Analytics has raised £4 million in Series A funding. The funding round was led by Hoxton Ventures with participation from Nesta and Mustard Seed Ventures.

Asklepios BioPharmaceutical, Inc., a leading, clinical-stage gene therapy company dedicated to developing adeno-associated virus (AAV) gene therapies for genetic disorders, has been awared a £1.99m R&D Grant from Scottish Enterprise.

AskBio will invest £3.4m alongside the grant to fund research into the manufacturing challenges associated with scaling gene therapies for widespread patient access, to further develop technologies to improve the safety and efficacy of current therapies, and to enable the treatment of genetic diseases with more complicated disease pathways that the industry is not yet able to address.

ClinSpec Diagnostics, a university spin-out which has developed a way to detect cancer at an early stage using a simple blood test, has completed a £2.4m funding round led by Mercia’s EIS funds.

Medefer, the b2b virtual healthcare provider that is reimagining the old-fashioned outpatient system, has announced a £10m funding round led by private investment firm Nickleby Capital. The growth funding will be used to invest in people and technology to service new contracts, enable new product development and ensure scalable and robust growth from its strong pipeline. The company, founded by NHS consultant Dr Bahman Nedjat-Shokouhi - who still works in the NHS - has been recognised as one of the top 100 most exciting digital health companies in the UK, by the DTI.   

A healthtech business with an app that helps patients communicate with clinicians remotely has raised a further £2m to help expand its use.

Advanced Digital Innovation (ADI) has raised funding from NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund, the UK government’s Future Fund and the company’s Chair and founder Bob Gomersall.

Advanced Digital Innovation (ADI) has raised funding from NPIF – Mercia Equity Finance, which is managed by Mercia and is part of the Northern Powerhouse Investment Fund, the UK government’s Future Fund and the company’s Chair and founder Bob Gomersall.  The Yorkshire-based company says the pandemic has boosted interest in its MyPathway app, which removes the need for appointment letters and calls, allowing patients to agree care plans with clinicians, who can then monitor their progress and receive feedback.

Liopa has successfully achieved funding from Innovate UK in its “Funding Competition for Business-led Innovation in Response to Global Disruption.” The financial award is part of a £40m package from the UK government to bolster technology and research-focused companies who are working to build resilience during the Covid crisis. 

A biotech company which is developing new treatments for patients with serious spinal conditions has completed a £2.25m funding round led by Mercia Asset Management to help to continue its ground-breaking research and bring its first products to market.

Neurovalens, a global healthtech company headquartered in Belfast and San Diego, has raised £5.1 million in funding, led by IQ Capital. Wharton Asset Management Company, The Angel CoFund (ACF), Techstart Ventures, Clarendon Fund Managers, and the Government’s Future Fund also contributed to the funding round, which will be used to expand on the success of Neurovalens’ initial clinical trials and develop the technology’s application for other conditions.

Leading digital health start-up Gendius has raised £250,000 on leading crowdfunding platform, Crowdcube, as downloads of its remote diabetes platform for diabetes, Intellin®, have also reached 250,000. Gendius has now overfunded on Crowdcube by over 500% 

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round led by transatlantic VC Epidarex Capital, with the Scottish Investment Bank, the investment arm of Scottish Enterprise, also investing. Company formation and in-licensing of the technology has been facilitated by Edinburgh Innovations, the commercialisation service for the University of Edinburgh. Macomics, which was spun out from the University of Edinburgh, will use the proceeds of this fundraising round to develop novel, first-in-class immunotherapies designed to modulate macrophages, increasing the body’s immune defence against tumours. 

Kelvin Capital backed ProFactor Pharma Ltd (PFP), has completed an important development milestone in its research that will transform the treatment of ‘Haemophilia A’.

Based outside Edinburgh at the Easter Bush Campus, the company has received £1.1m (the second tranche of funding from its £2m funding round announced in September 2019) to advance its R&D programme, which is moving closer to toxicology studies for its low cost recombinant human factor VIII (rhFVIII) for the treatment of ‘Haemophilia A’.